Quantinno Capital Management LP Acquires 36,467 Shares of Omeros Corporation $OMER

Quantinno Capital Management LP lifted its stake in Omeros Corporation (NASDAQ:OMER) by 145.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 61,541 shares of the biopharmaceutical company’s stock after acquiring an additional 36,467 shares during the period. Quantinno Capital Management LP owned approximately 0.09% of Omeros worth $650,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of OMER. UBS Group AG increased its holdings in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after purchasing an additional 1,513,893 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Omeros by 85.2% in the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company’s stock valued at $1,897,000 after buying an additional 82,646 shares during the period. Corient Private Wealth LLC grew its position in Omeros by 13.0% during the fourth quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock worth $11,817,000 after buying an additional 79,263 shares in the last quarter. AlphaQuest LLC grew its position in Omeros by 8,259,600.0% during the fourth quarter. AlphaQuest LLC now owns 82,597 shares of the biopharmaceutical company’s stock worth $1,419,000 after buying an additional 82,596 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Omeros by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after buying an additional 666,357 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on OMER shares. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. HC Wainwright restated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Finally, Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Omeros presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Insider Buying and Selling at Omeros

In other news, Director Thomas J. Cable sold 7,500 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the sale, the director owned 35,067 shares in the company, valued at approximately $407,127.87. The trade was a 17.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO David J. Borges sold 5,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $16.95, for a total transaction of $84,750.00. Following the completion of the sale, the chief accounting officer directly owned 5,000 shares in the company, valued at approximately $84,750. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.50% of the company’s stock.

Omeros Trading Up 7.0%

NASDAQ OMER opened at $18.39 on Thursday. The stock’s 50 day moving average is $11.35 and its two-hundred day moving average is $11.66. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of 14.37 and a beta of 2.54. Omeros Corporation has a 1-year low of $3.94 and a 1-year high of $18.89.

Omeros (NASDAQ:OMER) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, analysts predict that Omeros Corporation will post -0.37 earnings per share for the current year.

Omeros Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.